Skip Navigation

Continuing Education in Anaesthesia, Critical Care & Pain 2006 6(1):17-22; doi:10.1093/bjaceaccp/mki061
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Elliot, C A
Right arrow Articles by Kiely, D G
Right arrow Search for Related Content
PubMed
Right arrow Articles by Elliot, C A
Right arrow Articles by Kiely, D G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Continuing Education in Anaesthesia, Critical Care & Pain | Volume 6 Number 1 2006 © The Board of Management and Trustees of the British Journal of Anaesthesia [2006]. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Pulmonary hypertension

C A Elliot, MB ChB MRCP, Clinical Lecturer Respiratory Medicine Sheffield Pulmonary Vascular Disease Unit
Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS, Foundation Trust, Sheffield, UK
Division of Genomic Medicine, University of Sheffield, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS, Foundation Trust, Sheffield, UK

D G Kiely, MD FCCP, Consultant Respiratory Physician with an interest in Pulmonary Vascular Disease
Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS, Foundation Trust, Sheffield, UK
Tel: 0114 2712590 Fax: 0114 2711718 E-mail: david.kiely@sth.nhs.uk (for correspondence)

The first 150 words of the full text of this article appear below.


Key points

Idiopathic pulmonary arterial hypertension may be rare but pulmonary hypertension is increasingly recognized in association with other disease processes.

Accurate clinical classification is crucial in the management of the disease.

There are effective treatments for pulmonary hypertension.

Nationally designated specialist centres exist to assist in the diagnosis and treatment of patients with pulmonary hypertension.

When patients have unexplained dyspnoea, particularly in high-risk groups, consider pulmonary hypertension.

 

Pulmonary hypertension is a rare condition previously associated with a relentless course and few treatment options. The last 10 years have seen it become increasingly recognized in association with other conditions and the development of effective therapies.

Pulmonary hypertension is defined as a mean pulmonary artery pressure (MPAP) ≥25 mm Hg at rest or 30 mm Hg on exercise.1 At the "World Symposium on Pulmonary Arterial Hypertension" in 2003, the clinical classification of pulmonary hypertension was revised2 to identify five major groups . . . [Full Text of this Article]


   Epidemiology
 

   Pathophysiology
 

   Clinical features
 

   Investigations
 
Electrocardiogram

Chest X-Ray

Pulmonary Function Tests

Trans-thoracic echocardiogram (TTE)


   Specialist assessment
 
Key Investigations


   Treatment
 

   Note in proof
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?